167 related articles for article (PubMed ID: 22310589)
1. Cyclosporine microemulsion formulation (sigmasporin microral) effect as first-line immunosuppressant on renal functions at 3 years.
Al Wakeel J; Shaheen FA; Al Alfi A; Abbas Fagir EH; Iman A; Nampoory MR; Al Mousawi MS; Said T; Abou Zeinab H; Shaker DS; Ghaedi BB
Transplant Proc; 2012 Jan; 44(1):94-100. PubMed ID: 22310589
[TBL] [Abstract][Full Text] [Related]
2. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abouzeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2252-7. PubMed ID: 18790206
[TBL] [Abstract][Full Text] [Related]
6. Low 1-year cyclosporine microemulsion doses are associated with better 5-year renal graft function: an insight from MOST, a multinational observational study.
Salvadori M; Rosati A; Bertoni E; Bock A; Chapman J; Dussol B; Fritsche L; Kliem V; Lebranchu Y; Oppenheimer F; Pohanka E; Tufveson G; Soergel M
Transplant Proc; 2006 May; 38(4):1010-3. PubMed ID: 16757247
[TBL] [Abstract][Full Text] [Related]
7. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients.
Kahn D; Muller E; Pascoe M
Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
Qazi YA; Forrest A; Tornatore K; Venuto RC
Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
[TBL] [Abstract][Full Text] [Related]
11. Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year.
Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Budde K; Waiser J; Luft FC
Nephrol Dial Transplant; 1996 Jan; 11(1):165-72. PubMed ID: 8649628
[TBL] [Abstract][Full Text] [Related]
12. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
14. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
Sharma A; Shekhar C; Heer M; Minz M
Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
[TBL] [Abstract][Full Text] [Related]
15. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
16. Long-term kidney transplant outcomes in patients receiving oil-based or microemulsion formulations of cyclosporine.
Medina-Pestana JO; Felipe CR; Park SI; Machado PG; Garcia R; Spinelli G; Silva LA; Santos CF; Tedesco-Silva H
Transplant Proc; 2004 Mar; 36(2 Suppl):74S-79S. PubMed ID: 15041311
[TBL] [Abstract][Full Text] [Related]
17. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
18. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients.
Briggs D; Dudley C; Pattison J; Pfeffer P; Salmela K; Rowe P; Tydén G;
Transplantation; 2003 Jun; 75(12):2058-63. PubMed ID: 12829912
[TBL] [Abstract][Full Text] [Related]
19. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
20. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
